Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.
Alejandro Gonzalez-SernaAnaïs Corma-GomezFrancisco TellezDiana Corona-MataMaría Jose Rios-VillegasDolores MerinoCarlos GaleraAntonio Ramon Collado-RomachoIgnacio De Los SantosJosep CucurullMarta SantosSofía García-MartínAntonio RiveroLuis Miguel RealJuan MacíasPublished in: The Journal of antimicrobial chemotherapy (2023)
G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- end stage renal disease
- antiretroviral therapy
- clinical practice
- hiv infected
- hiv positive
- chronic kidney disease
- ejection fraction
- newly diagnosed
- hiv aids
- hiv testing
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- preterm birth
- smoking cessation
- gestational age